Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420702 | 0.85 | F2 (0.62) | F2PRSS1CASP1ALDH1A1HDAC8 | |
| SCHEMBL8367165 | 0.82 | F2 (0.63) | F2PRSS1CASP1 | |
| SCHEMBL23460649 | 0.82 | ELANE (0.47) | F2PRSS1ALDH1A1KDM4EELANE | |
| SCHEMBL4424252 | 0.81 | ELANE (0.61) | F2PRSS1CASP1ELANE | |
| SCHEMBL4421701 | 0.81 | F2 (0.73) | F2PRSS1 | |
| SCHEMBL23460591 | 0.79 | KDM4E (0.43) | F2PRSS1PLA2G10PLA2G5ALDH1A1 | |
| SCHEMBL30765994 | 0.77 | ELANE (0.46) | F2ALDH1A1KDM4EELANE | |
| SCHEMBL23461186 | 0.74 | F2 (0.49) | F2PRSS1ALDH1A1KDM4E | |
| SCHEMBL30765952 | 0.74 | ELANE (0.41) | F2ALDH1A1KDM4EELANE | |
| SCHEMBL23460572 | 0.74 | F2 (0.57) | F2PRSS1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | SERPINC1, TFPI, SERPINE1 | F2 7/4885PRSS1 86/4885CASP1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.